Tedros said the risk posed by monkeypox is moderate globally, but the threat is high in Europe. There’s clearly a risk that the virus will continue to spread around the world, he said, though it’s unlikely to disrupt global trade or travel right now.

In early May, the United Kingdom reported a case of monkeypox in a person who recently returned from travel to Nigeria. Several days later, the U.K. reported three more cases of monkeypox in people who appeared to have become infected locally. Other European nations, Canada and the U.S. then also began confirming cases. It’s unclear where the outbreak actually began.

The WHO last issued a global health emergency in January 2020 in response to the Covid-19 outbreak and two months later declared it a pandemic. The WHO has no official process to declare a pandemic under its organizational laws, which means the term is loosely defined. In 2020, the agency declared Covid a pandemic in an effort to warn complacent governments about the “alarming levels of spread and severity” of the virus.

LONDON (AP) — The chief of the World Health Organization said the expanding monkeypox outbreak in more than 70 countries is an “extraordinary” situation that now qualifies as a global emergency, a declaration Saturday that could spur further investment in treating the once-rare disease and worsen the scramble for scarce vaccines.

WHO Director-General Tedros Adhanom Ghebreyesus made the decision to issue the declaration despite a lack of consensus among experts serving on the U.N. health agency’s emergency committee. It was the first time the chief of the U.N. health agency has taken such an action.

“We have an outbreak that has spread around the world rapidly through new modes of transmission about which we understand too little and which meets the criteria in the international health regulations,” Tedros said.

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was completed, prompting the Centers for Disease Control and Prevention (CDC) to issue a health advisory on this so-called “COVID-19 rebound.”

In a study published June 20, 2022 in Clinical Infectious Diseases, researchers at University of California San Diego School of Medicine evaluated one such patient and found their symptom relapse was not caused by the development of resistance to the drug or impaired immunity against the virus. Rather, the COVID-19 rebound appears to have been the result of insufficient exposure to the drug.